US Pharma MarketingFDA leaders say they’ve woven in feedback as expedited trial program goes live
FDA Topic Hubs AI drug discovery: News, analysis and interviews Antibody-drug conjugates: The next wave of targeted cancer drugs Biopharma M&A and dealmaking: Who’s buying and why Biopharma people moves: CEO changes, executive hires, board positions Biotech IPOs: Tracking the market for new public offerings Biotech venture funding: Who’s raising and where the money is going Cell and gene therapy manufacturing: Scaling the next frontier China biotech: Licensing deals and the Biosecure Act CRISPR and gene editing: The push for in vivo therapies Drug pricing and the IRA: Tracking the government's negotiation power FDA policy and drug approvals: What’s changing…
The FDA’s long-awaited expedited investigational new drug pilot program began accepting applications Tuesday, with top agency officials incorporating public feedback into who should qualify.
Karim Mikhail and Michael Davis, the newly named permanent directors of ...
Source: Endpoints News